Excited for the future results!
Theralase®'s "Rutherrin®, has been proven effective preclinically in the destruction of Non-Small Cell Lung Cancer ("NSCLC")"
Theralase Technologies (TSXV: TLT)
Pharmaceutical Manufacturing
Toronto, ON 990 followers
Destroying cancer at the speed of light
About us
Theralase® Technologies is a Canadian clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers. We strive to continuously improve the quality of life for those afflicted with cancer by focusing our research and development on preventing, alleviating and treating diseases. Serving our higher purpose to bring hope for cancer treatments to light. Founded in 1994, Theralase’s operations are divided into two divisions: the production of therapeutic laser technology for commercial applications, and the research and development of laser-based technologies for the destruction of cancer cells and other disease states. Theralase® is focused on the discovering, developing and aiming for commercialization of Anti-Cancer therapies using light-activated PhotoDynamic Compounds and their associated drug formulations to safely and effectively treat patients afflicted with cancer.
- Website
-
https://linktr.ee/theralasetechnologiesinc
External link for Theralase Technologies (TSXV: TLT)
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Toronto, ON
- Type
- Public Company
- Founded
- 1994
- Specialties
- Photodynamic Compounds, Bladdercancer, Anti-Cancer, pharmaceutical, Medical Device, Healthcare, and Cancer Research
Locations
-
Primary
Get directions
41 Hollinger Road
Toronto, ON M4B 3G4, CA
Employees at Theralase Technologies (TSXV: TLT)
-
Matthew Perraton FMA, DFSA, Pro.Dir
Investor Relations officer with Theralase Technologies Inc. working towards the next standard of care for bladder cancer
-
Wayne Embree
Specialty Food
-
Mark Roufaiel
Research Scientist | Cancer Therapy, Immunology, and Cardiovascular Disease | From Preclinical Development to Translation into Clinical Applications.
-
Dr. James W. Gregg D.C., F.I.C.P.A
Owner at Gregg Chiropractic Life Centre
Updates
-
Very exciting uppdate!
Theralase Update"...inactivate 90 to 99.9% of all seven viruses that we tested, including H1N1 influenza virus, coronavirus, Zika virus, poxvirus and herpes virus. In fact, RuvidarTM at 3 mM completely killed the herpes virus."
Theralase(R) Technology Effective in Virus Inactivation
accesswire.com
-
Q&A clip with Theralase® CEO; full video on website www.theralase.com
-
Very exciting news from Theralase!
Theralase granted Canadian patent for cancer vaccine technology
proactiveinvestors.com
-
Theralase® Release’s 2023 Annual Financial Statements and provides update to clinical trial. https://zc.vg/QTb2u?m=0
Theralase® Release 2023 Annual Financial Statements
rals-zgpm.campaign-view.com
-
Video - Order of Canada Recipient Dr. Jewett Discussing New Role with Theralase. https://lnkd.in/gdg9SHxS
Theralase Technologies (TSXV: TLT) | LinkedIn
ca.linkedin.com
-
Possible new treatment for Parkinson's Disease
Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease
accesswire.com
-
Very exciting new addition to our team Bladder Cancer Canada, University Health Network
Order of Canada recipient joining the Theralase team!
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
accesswire.com
-
Theralase provides update on Bladder Cancer trial results
Update on Theralase results
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
accesswire.com